You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,096,505


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,096,505
Title: Noncloning technique for expressing a gene of interest
Abstract:A noncloning method for expressing a gene of interest in a mammalian host cell is disclosed. The invention utilizes three basic individual elements: (1) a promoter element; (2) at least one gene of interest; and (3) a selectable marker cassette which includes in 5\' to 3\' order, an internal ribosome entry site (\"IRES\"), at least one gene coding for a selectable marker, and a transcription termination sequence. The three individual elements are cotransfected into a mammalian host cell where they become operably linked such that expression of the selectable marker gene(s) necessarily requires coexpression of the gene of interest.
Inventor(s): Selby; Mark (San Francisco, CA), Thudium; Kent B. (Oakland, CA), Dina; Dino (Oakland, CA)
Assignee: Chiron Corporation (Emeryville, CA)
Application Number:09/290,449
Patent Claims:1. A method of expressing at least one recombinant polypeptide comprising:

(a) providing as separate elements (i) a first nucleic acid element which comprises a promoter, (ii) a second nucleic acid element which comprises at least one selectable marker gene conferring a selectable phenotype on a cell transfected therewith, an internal ribosome entry site (IRES) sequence positioned upstream of the selectable marker gene, and a transcription termination sequence positioned downstream of the selectable marker gene, and (iii) a third nucleic acid element which comprises at least one gene encoding said at least one polypeptide;

(b) cotransfecting a population of mammalian cells with each of said first, second and third elements;

(c) culturing said population of cells under conditions whereby the polypeptide and the at least one selectable marker are expressed;

(d) selecting cells which express the selectable marker; and

(e) identifying those cells from the selected cells that express the recombinant polypeptide.

2. The method of claim 1, wherein the promoter is the human cytomegalovirus (CMV) immediate-early enhancer/promoter and includes the CMV intron A.

3. The method of claim 1, wherein the at least one selectable marker gene comprises a dhfr gene.

4. The method of claim 1, wherein the IRES sequence is derived from encephalomyocarditis virus.

5. The method of claim 1, wherein the third nucleic acid element is a cDNA library.

6. The method of claim 1, wherein the third nucleic acid element is a PCR product.

7. The method of claim 1, wherein the third nucleic acid element is from a DNA virus.

8. The method of claim 1, wherein the gene of the third nucleic acid element is bounded on its 5' end with a nucleotide sequence of about 3 to about 150 nucleotides complementary to the 3' end of the first nucleic acid element, and bounded on its 3' end with a nucleotide sequence of about 3 to about 150 nucleotides, complementary to the 5' end of the second nucleic acid element.

9. The method of claim 1, wherein the at least one selectable marker gene comprises a neo.sup.r gene.

10. The method of claim 9, wherein the neo.sup.r gene is neo.sub.(m2) which confers reduced resistance to geneticin on a cell transfected therewith as compared to the wild-type neo.sup.r gene.

11. The method of claim 1, wherein the polypeptide encoded by the third nucleic acid element is a viral protein.

12. The method of claim 11, wherein the viral protein is a hepatitis virus protein.

13. The method of claim 12, wherein the hepatitis protein is a hepatitis B virus (HBV) protein.

14. The method of claim 13, wherein the HBV protein is HBV preS2.

15. A method of expressing at least one recombinant polypeptide comprising:

(a) providing as separate elements (i) a first nucleic acid element which comprises a promoter, (ii) a second nucleic acid element which comprises at least one selectable marker gene selected from the group consisting of a neo.sup.r gene and a dhfr gene, an encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES) sequence positioned upstream of the selectable marker gene, and a transcription termination sequence positioned downstream of the selectable marker gene, and (iii) a third nucleic acid element which comprises at least one gene encoding said at least one polypeptide, wherein the gene is bounded on its 5' end with a nucleotide sequence of about 3 to about 150 nucleotides complementary to the 3' end of the first nucleic acid element, and bounded on its 3' end with a nucleotide sequence of about 3 to about 150 nucleotides, complementary to the 5' end of the second a nucleic acid element;

(b) cotransfecting a population of mammalian cells with each of said first, second and third elements;

(c) culturing said population of cells under conditions whereby the polypeptide and the at least one selectable marker are expressed;

(d) selecting cells which express the selectable marker; and

(e) identifying those cells from the selected cells that express the recombinant polypeptide.

16. The method of claim 15, wherein the promoter is the human cytomegalovirus (CMV) immediate-early enhancer/promoter and includes the CMV intron A.

17. The method of claim 15, wherein the neo.sup.r gene is NEO.sub.(m2) which confers reduced resistance to geneticin on a cell transfected therewith as compared to the wild-type neo.sup.r gene.

18. The method of claim 15, wherein the third nucleic acid element is a cDNA library.

19. The method of claim 15, wherein the third nucleic acid element is a PCR product.

20. The method of claim 15, wherein the third nucleic acid element is from a DNA virus.

21. The method of claim 15, wherein the second nucleic acid element comprises both a neo.sup.r gene and a dhfr gene.

22. The method of claim 21, wherein the neo.sup.r gene is positioned downstream of the dhfr gene.

23. The method of claim 22, wherein the stop codon for the dhfr gene is replaced with a spacer of about 3 to about 150 nucleotides, such that transcription and translation of both the dhfr and neo.sup.r genes occurs.

24. The method of claim 23, wherein the spacer is about 12 to about 18 nucleotides.

25. The method of claim 15, wherein the polypeptide encoded by the third nucleic acid element is a viral protein.

26. The method of claim 25, wherein the viral protein is a hepatitis virus protein.

27. The method of claim 26, wherein the hepatitis protein is a hepatitis B virus (HBV) protein.

28. The method of claim 27, wherein the HBV protein is HBV preS2.

29. A selectable marker nucleic acid element comprising: (a) a neo.sup.r gene, (b) a dhfr gene positioned upstream of the neo.sup.r gene, wherein the stop codon for the dhfr gene is replaced with a spacer of about 3 to about 150 nucleotides, such that transcription and translation of both the dhfr and neo.sup.r genes occurs, (c) an internal ribosome entry site (IRES) sequence positioned upstream of the dhfr gene, (d) and a transcription termination sequence positioned downstream of the neo.sup.r gene.

30. The selectable marker element of claim 29, wherein the neo.sup.r gene is NEO.sub.(m2) which confers reduced resistance to geneticin on a cell transfected therewith as compared to the wild-type neo.sup.r gene.

31. The selectable marker element of claim 29, wherein the IRES sequence is derived from encephalomyocarditis virus.

32. The selectable marker element of claim 29, wherein the transcription termination sequence is a bovine growth hormone transcription termination sequence.

33. The selectable marker element of claim 29, wherein the spacer is about 12 to about 18 nucleotides.

34. A mammalian host cell transfected with the selectable marker nucleic acid element of claim 29.

35. A selectable marker nucleic acid element comprising: (a) a neo.sup.r gene is NEO.sub.(m2) which which confers reduced resistance to geneticin on a cell transfected therewith as compared to the wild-type neo.sup.r gene, (b) a dhfr gene positioned upstream of the neo.sup.r gene, wherein the stop codon for the dhfr gene is replaced with a spacer of about 12 to about 18 nucleotides, such that transcription and translation of both the dhfr and neo.sup.r genes occurs, (c) an encephalomyocarditis virus internal ribosome entry site (IRES) sequence positioned upstream of the dhfr gene, (d) and a bovine growth hormone transcription termination sequence positioned downstream of the neo.sup.r gene.

36. A mammalian host cell transfected with the selectable marker nucleic acid element of claim 35.

Details for Patent 6,096,505

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2018-04-14
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2018-04-14
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2018-04-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.